新浪登录
腾讯登录BioMark联手TMIC，合作开发新型癌症诊断技术
| 导读 | BioMark Diagnostics近日宣布其正式达成与加拿大代谢组学创新中心（TMIC）的合作共同开展癌症研究工作。 |
BioMark Diagnostics（http://www.biomarkdiagnostics.com）近日宣布其正式达成与加拿大代谢组学创新中心（TMIC：http://www.metabolomicscentre.ca/）的合作共同开展癌症研究工作。
BioMark在声明中表示，该项合作将促进BioMark公司代谢组学分子诊断测试的开发、认证与转化，该公司计划在肺癌、前列腺癌、乳腺癌和结肠癌的研究中应用其新型分子诊断技术。
通过与TMIC合作,BioMark计划开发新型单点性医疗诊断测试。BioMark致力于开发非侵入性诊断技术来检测癌症,监测患者和评估疾病治疗。TMIC是加拿大政府投资兴建的基因组学科技创新中心，专注于代谢组学研究、技术开发与相关服务的提供，TMIC拥有成熟的质谱技术,核磁共振,气相色谱以及最先进的生物信息学工具。
（转化医学网360zhyx.com）以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。
转化医学网推荐的新闻阅读：NEW YORK (GenomeWeb) – BioMark Diagnostics today announced it is partnering with The Metabolomics Innovation Centre on cancer research.
The deal augments BioMark's efforts to discover, validate, and translate metabolomics-based diagnostic tests for early cancer detection, the Vancouver, British Columbia-based firm said, adding it "complements" its planned research into lung, prostate, breast, and colon cancer.
In collaboration with TMIC, BioMark plans to develop novel point-of-care diagnostic tests.
BioMark develops non-invasive technologies to detect cancers, monitor patients, and assess disease treatments. TMIC is a Genome Canada-funded Science & Technology Innovation Centre for metabolomics research, technology development, and services. Its technologies are based on mass spectrometry, NMR, gas chromatography, and novel bioinformatics tools.
还没有人评论，赶快抢个沙发